These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 32081238)

  • 41. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
    Gouëffic Y; Torsello G; Zeller T; Esposito G; Vermassen F; Hausegger KA; Tepe G; Thieme M; Gschwandtner M; Kahlberg A; Schindewolf M; Sapoval M; Diaz-Cartelle J; Stavroulakis K;
    Circulation; 2022 Nov; 146(21):1564-1576. PubMed ID: 36254728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.
    Wooster M; Dansey K; Shames M
    Vasc Endovascular Surg; 2016 Feb; 50(2):80-3. PubMed ID: 26912397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.
    Soga Y; Fujihara M; Tomoi Y; Iida O; Ishihara T; Kawasaki D; Ando K
    J Atheroscler Thromb; 2020 Feb; 27(2):164-171. PubMed ID: 31257301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
    Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
    Tomoi Y; Soga Y; Iida O; Fujihara M; Ando K
    J Endovasc Ther; 2017 Oct; 24(5):640-646. PubMed ID: 28675951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
    Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
    J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence and its characteristics of repetition of reintervention after drug-eluting stent implantation for femoropopliteal lesion.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Yokoi H; Uematsu M;
    J Vasc Surg; 2016 Dec; 64(6):1691-1695.e1. PubMed ID: 27575807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
    Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
    Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
    Dake MD; Fanelli F; Lottes AE; O'Leary EE; Reichert H; Jiang X; Fu W; Iida O; Zen K; Schermerhorn M; Zeller T; Ansel GM
    Cardiovasc Intervent Radiol; 2021 Feb; 44(2):196-206. PubMed ID: 33025243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of Vascular Patency and Inflammation with Intravascular Optical Coherence Tomography in Patients with Superficial Femoral Artery Disease Treated with Zilver PTX Stents.
    Hoyt T; Feldman MD; Okutucu S; Lendel V; Marmagkiolis K; McIntosh V; Ates I; Kose G; Mego D; Paixao A; Iliescu C; Park J; Shaar M; Avci R; McElroy A; Dijkstra J; Milner TE; Cilingiroglu M
    Cardiovasc Revasc Med; 2020 Jan; 21(1):101-107. PubMed ID: 31395436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
    J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease.
    Ansel GM; Jaff MR; Popma JJ; Battisti AJ; Lottes AE; Harnish P; Dake MD
    J Endovasc Ther; 2017 Aug; 24(4):499-503. PubMed ID: 28485182
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
    J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vascular Response After FP-PES Versus Polymer-Free Paclitaxel-Eluting Stent Implantation in Femoropopliteal Artery Lesions: A Serial Intravascular Ultrasound Study.
    Tomoi Y; Kuramitsu S; Soga Y; Fujihara M; Iida O; Kawasaki D; Ando K
    JACC Cardiovasc Interv; 2020 Feb; 13(4):535-537. PubMed ID: 32081246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.